- Previous Close
2,595.00 - Open
2,590.00 - Bid 2,515.00 x --
- Ask 2,535.00 x --
- Day's Range
2,500.00 - 2,605.00 - 52 Week Range
2,100.00 - 8,500.00 - Volume
44,194 - Avg. Volume
612,248 - Market Cap (intraday)
38.415B - Beta (5Y Monthly) 0.12
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date Nov 12, 2024 - Nov 18, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Gencurix Inc. provide diagnostic solutions in South Korea. Its products include GenesWell BCT, a prognosis diagnostic test for breast cancer; GenesWell ddEGFR Mutation Test, a companion test for lung cancer; Droplex, a genetic test that detects DNA mutations; eDX, an early diagnosis for cancer with liquid biopsy; GenePro COVID-19 detection test; GenePro SARS-CoV-2 Test kit; GenoCTC (circulating tumor cell isolator); GenePro LAMP test solution for rapid, convenient and simple detection of various infectious diseases; and GenePro LAMP Cycler, a device for loop-mediated isothermal amplification. The company was founded in 2011 and is headquartered in Seoul, South Korea.
www.gencurix.com69
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 229000.KQ
View MorePerformance Overview: 229000.KQ
Trailing total returns as of 10/18/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 229000.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 229000.KQ
View MoreValuation Measures
Market Cap
38.41B
Enterprise Value
48.39B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
12.49
Price/Book (mrq)
3.62
Enterprise Value/Revenue
16.60
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-23.43%
Return on Equity (ttm)
-112.87%
Revenue (ttm)
2.91B
Net Income Avi to Common (ttm)
-14.25B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
773.79M
Total Debt/Equity (mrq)
125.39%
Levered Free Cash Flow (ttm)
-5.22B